Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.
作者信息
Black Gage S, Huang Xiaomeng, Qiao Yi, Tarapcsak Szabolcs, Rogers Kerry A, Misra Shrilekha, Byrd John C, Marth Gabor T, Stephens Deborah M, Woyach Jennifer A
机构信息
Department of Human Genetics, University of Utah, Salt Lake City, UT;
Utah Center for Genetic Discovery, School of Medicine, University of Utah, Salt Lake City, UT.
出版信息
Blood. 2022 Jul 28;140(4):401-405. doi: 10.1182/blood.2021015132.
Abstract
摘要
相似文献
1
Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients.慢性淋巴细胞白血病驱动基因突变的亚克隆进化与接受依鲁替尼和阿卡拉布替尼治疗的患者复发相关。
Blood. 2022 Jul 28;140(4):401-405. doi: 10.1182/blood.2021015132.
2
Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.初治慢性淋巴细胞白血病患者开始一线应用伊布替尼或阿卡替尼的治疗时间。
Future Oncol. 2024 Jan;20(1):39-53. doi: 10.2217/fon-2023-0436. Epub 2023 Jul 21.
3
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.阿卡拉布替尼用于对依鲁替尼不耐受的复发/难治性慢性淋巴细胞白血病患者的II期研究。
Haematologica. 2021 Sep 1;106(9):2364-2373. doi: 10.3324/haematol.2020.272500.
4
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.评估阿卡替尼在治疗慢性淋巴细胞白血病中的药代动力学。
Expert Opin Drug Metab Toxicol. 2021 Sep;17(9):1023-1030. doi: 10.1080/17425255.2021.1955855. Epub 2021 Jul 28.
5
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.布鲁顿酪氨酸激酶抑制剂停药后慢性淋巴细胞白血病的治疗。
Hematol Oncol Clin North Am. 2021 Aug;35(4):793-806. doi: 10.1016/j.hoc.2021.03.008. Epub 2021 May 27.
6
Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.布鲁顿酪氨酸激酶抑制剂可抑制慢性淋巴细胞白血病中 FcγRIIA 介导的血小板对细菌的反应。
Front Immunol. 2021 Nov 29;12:766272. doi: 10.3389/fimmu.2021.766272. eCollection 2021.
7
Screening and monitoring of the BTK mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.在依鲁替尼治疗期间，对复发/难治性慢性淋巴细胞白血病真实世界队列患者进行布鲁顿酪氨酸激酶（BTK）突变的筛查和监测。
Br J Haematol. 2021 Jul;194(2):355-364. doi: 10.1111/bjh.17502. Epub 2021 May 21.
8
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.泽布替尼用于对伊布替尼和/或阿卡拉布替尼不耐受的B细胞恶性肿瘤患者的II期研究中患者的基因组概况。
Haematologica. 2024 Jul 1;109(7):2284-2289. doi: 10.3324/haematol.2023.283861.
9
Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.阿卡替尼及其在慢性淋巴细胞白血病治疗中的应用。
Future Oncol. 2022 Mar;18(7):755-769. doi: 10.2217/fon-2021-0602. Epub 2022 Feb 10.
10
Targeting Bruton's Tyrosine Kinase in CLL.针对慢性淋巴细胞白血病中的布鲁顿酪氨酸激酶。
Front Immunol. 2021 Jun 23;12:687458. doi: 10.3389/fimmu.2021.687458. eCollection 2021.
引用本文的文献
1
Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotypes and phenotypes in chronic lymphocytic leukemia.长读长单细胞RNA测序有助于研究慢性淋巴细胞白血病中癌症亚克隆特异性基因型和表型。
Genome Res. 2025 Apr 14;35(4):686-697. doi: 10.1101/gr.279049.124.
2
A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中布鲁顿酪氨酸激酶抑制剂耐药机制的研究进展。
Int J Mol Sci. 2024 May 11;25(10):5246. doi: 10.3390/ijms25105246.
3
Long-read single-cell RNA sequencing enables the study of cancer subclone-specific genotype and phenotype in chronic lymphocytic leukemia.长读长单细胞RNA测序能够研究慢性淋巴细胞白血病中癌症亚克隆特异性的基因型和表型。
bioRxiv. 2024 Mar 16:2024.03.15.585298. doi: 10.1101/2024.03.15.585298.
4
Targeting the NTSR2/TrkB oncogenic pathway in chronic lymphocytic leukemia.靶向慢性淋巴细胞白血病中的 NTSR2/TrkB 致癌通路。
Sci Rep. 2024 Mar 13;14(1):6084. doi: 10.1038/s41598-024-56663-5.
5
Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL.慢性淋巴细胞白血病（CLL）患者接受布鲁顿酪氨酸激酶（BTK）抑制剂治疗期间在真实世界临床测序中检测到的突变
Res Sq. 2024 Jan 16:rs.3.rs-3837426. doi: 10.21203/rs.3.rs-3837426/v1.
6
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax.对 BTK 抑制剂和 venetoclax 耐药的 CLL 的新型治疗方法和联合治疗。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):316-322. doi: 10.1182/hematology.2022000344.
本文引用的文献
1
B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation.B 细胞受体信号转导以及 TP53 和 CDKN2A/CDKN2B 的遗传病变在里希特转化中共同作用。
Blood. 2021 Sep 23;138(12):1053-1066. doi: 10.1182/blood.2020008276.
2
Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL.染色质绘图和单细胞免疫分析定义了伊布替尼治疗 CLL 反应的时间动态。
Nat Commun. 2020 Jan 29;11(1):577. doi: 10.1038/s41467-019-14081-6.
3
Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.通过对伊布替尼治疗的慢性淋巴细胞白血病患者进行时间突变分析来剖析亚克隆进化。
Int J Cancer. 2020 Jan 1;146(1):85-93. doi: 10.1002/ijc.32502. Epub 2019 Jun 25.
4
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.克隆多样性预测慢性淋巴细胞白血病的不良结局。
Leukemia. 2019 Feb;33(2):390-402. doi: 10.1038/s41375-018-0215-9. Epub 2018 Jul 23.
5
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.616 例美国伊布替尼治疗患者的毒性和结局：真实世界分析。
Haematologica. 2018 May;103(5):874-879. doi: 10.3324/haematol.2017.182907. Epub 2018 Feb 1.
6
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.伊布替尼靶向治疗慢性淋巴细胞白血病的进化景观。
Nat Commun. 2017 Dec 19;8(1):2185. doi: 10.1038/s41467-017-02329-y.
7
Clonal evolution in leukemia.白血病中的克隆进化。
Nat Med. 2017 Oct 6;23(10):1135-1145. doi: 10.1038/nm.4410.
8
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.阿卡拉布替尼（ACP-196）：一种具有独特选择性和体内药效学特征的共价布鲁顿酪氨酸激酶抑制剂。
J Pharmacol Exp Ther. 2017 Nov;363(2):240-252. doi: 10.1124/jpet.117.242909. Epub 2017 Sep 7.
9
BTK-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.布鲁顿酪氨酸激酶介导的慢性淋巴细胞白血病对依鲁替尼的耐药性
J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 Feb 13.
10
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.导致慢性淋巴细胞白血病对伊布替尼耐药的克隆进化。
Blood. 2017 Mar 16;129(11):1469-1479. doi: 10.1182/blood-2016-06-719294. Epub 2017 Jan 3.
Zotero 插件